Cancer Precision Medicine – Putting the Patient First
Our Mission
NanoMab is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of next generation radiopharmaceuticals.
Temperature and pH Resistant
Smaller Size for More Binding Options
Multivalent and Radiolabeling
Low Cost Production (Pichia / E.coli)
LEARN MORE ABOUT US AND OUR TECHNOLOGY
We are developing medicine for fast and specific delivery of radiation to treat cancer. A therapeutic product is made by a camelid antibody labelled with a radioisotope of therapeutic radiation.
COLLABORATORS
MANAGEMENT
Leadership Team
Nanomab is led by a highly experienced executive team with decades of experience across the pharmaceutical and life science sectors.
Board of Directors
The Nanomab board is comprised of an expert range of senior executives and life science professionals with a deep variety of business experience.
Scientific Advisory Board
Nanomab is advised by an expert group of scientists with vast research experience across radiopharmaceuticals, oncology and pharmaceuticals.